Klotho Neurosciences Highlights Pipeline Progress Toward $8B Neurodegenerative Market; Accelerates KLTO-202 Preclinical and IND-Enabling Studies

Author: Benzinga Newsdesk | August 18, 2025 08:37am

Key partnerships, regulatory  progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company's key milestones and pipeline progress. These achievements strengthen Klotho's position as it advances toward the large and growing market for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease therapies, which is estimated at over $8 billion annually by Grand View Research and others.

Building on its 2025 progress, the Company is positioned to pursue the following key objectives:

• Accelerate preclinical and IND-enabling studies for KLTO-202.
• Evaluate complementary technologies and acquisitions to enhance pipeline breadth in brain health, organ function, and longevity.
• Continue expanding internal capabilities to strengthen R&D, manufacturing, and clinical readiness.

Posted In: KLTO